Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Authors' Reply.

Victor Bobée1, Philippe Ruminy1, Vinciane Marchand1

  • 1INSERM U1245 Team 03, Centre Henri Becquerel, Rouen.

The Journal of Molecular Diagnostics : JMD
|February 28, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

Blood advances·2026
Same author

Peri-Operative Detection of Circulating Tumor DNA Using a Customized NGS Tumor-Informed Assay in Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma.

International journal of cancer·2026
Same author

Molecular determinants of cardiac lymphatic dysfunction in a chronic pressure-overload model.

EMBO molecular medicine·2025
Same author

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
This summary is machine-generated.

This response addresses a letter concerning MYD88 mutations and ibrutinib therapy sensitivity. It clarifies the authors

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Ibrutinib is a Bruton tyrosine kinase inhibitor used in treating B-cell malignancies.
  • MYD88 mutations are implicated in the pathogenesis and drug response of certain B-cell cancers.
  • Sensitivity to ibrutinib therapy can be influenced by specific genetic mutations.

Related Experiment Videos